Cryoport Reports Q2 2026 Revenue Growth of 8%, Achieves Positive Adjusted EBITDA Milestone
核心洞察
Cryoport (搜索)'s total Q2 2026 revenue reached $49.0 million, an 8% year-over-year increase driven by 15% growth in Life Sciences Services and 25% growth in BioStorage/BioServices.
The company achieved positive adjusted EBITDA from continuing operations of $0.4 million, marking an important milestone on its pathway to sustainable profitability.
Cryoport (搜索) now supports a record 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.
Cryoport (搜索), Inc. (NASDAQ: CYRX), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, reported second quarter 2026 financial results that underscore the company's expanding role in the cell and gene therapy (CGT) ecosystem. Total revenue for the quarter reached $49.0 million, representing an 8% year-over-year increase from $45.5 million in Q2 2025. The results reflect sustained momentum across the company's key business segments and meaningful progress toward sustainable profitability.
Jerrell Shelton, CEO of Cryoport (搜索), stated, "Our revenue momentum over the past several periods continued into the second quarter, with total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices revenue."
Life Sciences Services Drives Growth
The Life Sciences Services segment, which accounted for 57% of total quarterly revenue, generated $28.0 million in Q2 2026, up 15% from $24.4 million in the prior-year period. Within this segment, BioStorage/BioServices revenue climbed 25% year-over-year to $5.6 million, reflecting strong demand for the company's expanded, integrated services offering that provides seamless, secure handling of temperature-sensitive materials across its global network.
Life Sciences Products revenue, representing 43% of total revenue, held steady at $21.0 million compared to $21.1 million in Q2 2025. The segment was supported by continued demand for MVE Biological Solutions' cryogenic systems and the successful introduction of new products.
For the first half of 2026, total revenue reached $96.8 million, compared to $86.5 million in H1 2025. Life Sciences Services contributed $54.9 million (up from $47.2 million), while Life Sciences Products generated $41.9 million (up from $39.3 million).
Commercial CGT and Clinical Trial Momentum
Revenue from supporting commercial cell and gene therapies grew 9% year-over-year to $9.4 million. Notably, the Life Sciences Services portion of commercial CGT revenue grew 26% year-over-year, driven by increasing numbers of patients treated in community settings and on an outpatient basis.
Total revenue from CGT clinical trial support increased 12% year-over-year to $13.4 million, as customers' clinical pipelines advanced and matured. As of June 30, 2026, Cryoport (搜索) supported a record 779 clinical trials globally, a net increase of 51 trials compared to June 30, 2025, with 94 of these trials in Phase 3. The company also supported 22 commercially approved cell and gene therapies.
Regulatory Milestones Within Customer Base
During Q2 2026, four of Cryoport (搜索)'s customers filed Biologics License Applications (BLA) or Marketing Authorization Applications (MAA). The quarter also saw notable regulatory achievements: Orca Bio (搜索) received FDA approval for TREGZI (搜索)™ as the first and only precision-engineered cell therapy for allogeneic stem cell transplant in adults with hematological malignancies (搜索). Additionally, Vertex Pharmaceuticals received supplemental FDA approval to expand the label of CASGEVY® for patients aged two years and older with either sickle cell disease (搜索) or transfusion-dependent beta thalassemia (搜索), making it the first approved gene therapy indicated for children as young as two for both conditions.
For the balance of 2026, Cryoport (搜索) anticipates another 11 possible BLA/MAA applications, five possible additional new therapy approvals, and one possible additional approval for label or geographic expansion from its customer base.
Pathway to Profitability
Cryoport (搜索) achieved a significant financial milestone in Q2 2026, reporting positive adjusted EBITDA from continuing operations of $0.4 million, compared to a negative $0.9 million in Q2 2025. For H1 2026, adjusted EBITDA was a negative $0.2 million, a substantial improvement from a negative $3.7 million in H1 2025.
Shelton commented, "Achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value of our strategic investments and operational initiatives we have executed over the past several years."
Total gross margin was 46.6% for Q2 2026, compared to 47.0% in Q2 2025. Life Sciences Services gross margin improved to 49.9% from 48.9%, while Life Sciences Products gross margin was 42.2% compared to 44.9%. Loss from continuing operations narrowed to $8.3 million from $12.0 million in the prior-year quarter.
The company held $396.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026.
Operational Developments
Several operational milestones marked the quarter. Cryoport (搜索) Systems' IntegriCell® cryopreservation services were selected by Verismo Therapeutics (搜索), a clinical-stage CAR T-cell therapy company developing a novel multi-chain KIR-CAR platform technology for solid tumors and B cell-associated disorders.
The company advanced toward the planned launch of BioServices operations at its Global Supply Chain Center in Paris, France, expected in Q4 2026, and continued progress toward launching its state-of-the-art Global Supply Chain Center in Santa Ana, California, also anticipated in Q4 2026. Additionally, Cryoport (搜索) shipped its first high-efficiency freezers manufactured at its Chengdu, China facility under a "made in China for China" strategy.
Shelton concluded, "We remain focused on executing our strategy, driving financial performance, and capitalizing on the significant opportunities before us. We expect upcoming growth catalysts in our business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services, will drive us to new heights in market position, growth, and productivity."